+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

ClearPoint Neuro

(NASDAQ:CLPT)

Intraday

$6.11

0[0.00%]

After-Hours

$6.11

0[0.00%]

Perks Buy Compare Brokers

$6.11

0[0.00%]

At close: May 9

$6.11

0[0.00%]

PreMarket: 4:00PM EDT

Q1 2024 Earnings were released on Tue May 7th, after the market close

The most recent conference call was at 16:30 PM, 3 days ago Click to view past webcast

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for ClearPoint Neuro Stock (NASDAQ:CLPT)

ClearPoint Neuro Stock (NASDAQ: CLPT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, May 07, 2024

ClearPoint Neuro Reaffirms FY24 Revenue $28M-$32M Vs $30.259M Est.
Benzinga Newsdesk - 2 days ago
ClearPoint Neuro Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $7.639M Beat $6.994M Estimate
Benzinga Newsdesk - 2 days ago

Monday, April 29, 2024

ClearPoint Neuro Received FDA Clearance For Prism Bone Anchor Accessory
Benzinga Newsdesk - Apr 29, 2024, 8:03AM

Tuesday, April 16, 2024

ClearPoint Neuro Congratulates Its Partner AviadoBio On First Patient Treated In Its ASPIRE-FTD Clinical Trial Evaluating AVB-101 For Frontotemporal Dementia With GRN Mutations
Benzinga Newsdesk - Apr 16, 2024, 4:23PM

Tuesday, March 19, 2024

ClearPoint Neuro Congratulates Its Partner PTC Therapeutics On Completion Of Biologics License Application Submission To FDA For Upstaza As A Treatment For AADC Deficiency
Benzinga Newsdesk - Mar 19, 2024, 8:17AM

Wednesday, March 13, 2024

ClearPoint Neuro shares are trading higher after the company reported better-than-expected Q4 financial results and reaffirmed FY24 revenue guidance. Also, Stifel reiterated a Buy rating on the stock and raised its price target from $8 to $9.
Benzinga Newsdesk - Mar 13, 2024, 1:40PM
Stifel Reiterates Buy on ClearPoint Neuro, Raises Price Target to $9
Benzinga Newsdesk - Mar 13, 2024, 8:45AM

Tuesday, March 12, 2024

ClearPoint Neuro Reaffirms 2024 Revenue Guidance Of $28M-$32M, Est $30.433M
Benzinga Newsdesk - Mar 12, 2024, 5:05PM
ClearPoint Neuro: Q4 Earnings Insights
Benzinga Insights - Mar 12, 2024, 4:30PM
ClearPoint Neuro Q4 2023 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $6.810M Beat $6.533M Estimate
Benzinga Newsdesk - Mar 12, 2024, 4:27PM
Earnings Scheduled For March 12, 2024
Benzinga Insights - Mar 12, 2024, 5:35AM

Monday, March 11, 2024

Earnings Outlook For ClearPoint Neuro
Benzinga Insights - Mar 11, 2024, 2:01PM
Journal Of Neurosurgery Publication Demonstrates Advantages Of ClearPoint Prism Neuro Laser Therapy System
Benzinga Newsdesk - Mar 11, 2024, 8:12AM

Thursday, February 29, 2024

ClearPoint Neuro Announces Pricing Of Public Offering Of 2,307,694 Shares At $6.50/Share
Benzinga Newsdesk - Feb 29, 2024, 8:47AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Feb 29, 2024, 8:07AM

Wednesday, February 28, 2024

ClearPoint Neuro Launches Proposed Public Offering Of Common Stock
Benzinga Newsdesk - Feb 28, 2024, 5:12PM
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Feb 28, 2024, 4:31PM

Wednesday, February 21, 2024

ClearPoint Neuro Announces FDA Clearance And First-In-Human Cases Performed With The New 2.2 Software Version And The Integrated Maestro Brain Model
Benzinga Newsdesk - Feb 21, 2024, 4:54PM

Wednesday, January 24, 2024

ClearPoint Neuro Announces Installation And First Procedure Using The ClearPoint Prism Neuro Laser Therapy System And Navigation System At Kaleida Health In Buffalo
Benzinga Newsdesk - Jan 24, 2024, 4:25PM

Monday, January 22, 2024

ClearPoint Neuro Reveals Receipt Of European Medical Device Regulation Clearance For The Manual SmartTwist MR Hand Drill And SmartTip MR Drill Kit
Benzinga Newsdesk - Jan 22, 2024, 4:09PM

Tuesday, January 16, 2024

ClearPoint Neuro Announces FDA Clearance For SmartFrame OR Stereotactic System
Benzinga Newsdesk - Jan 16, 2024, 8:00AM

Tuesday, January 09, 2024

ClearPoint Neuro shares are trading higher after the company reported preliminary Q4 and FY23 revenue above estimates.
Benzinga Newsdesk - Jan 9, 2024, 11:26AM

Monday, January 08, 2024

ClearPoint Neuro Sees Prelim. FY23 Revenue $24M Vs $23.37M Est.
Benzinga Newsdesk - Jan 8, 2024, 4:14PM
ClearPoint Neuro Sees Prelim. Q4 Revenue $6.8M Vs $6.22M Est.
Benzinga Newsdesk - Jan 8, 2024, 4:13PM

Friday, November 10, 2023

ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY23 revenue guidance below estimates.
Benzinga Newsdesk - Nov 10, 2023, 11:49AM

Thursday, November 09, 2023

ClearPoint Neuro Sees FY23 Revenue $23M-$25M Vs $25.9M Est.
Benzinga Newsdesk - Nov 9, 2023, 6:06PM
ClearPoint Neuro: Q3 Earnings Insights
Benzinga Insights - Nov 9, 2023, 4:30PM
ClearPoint Neuro Q3 2023 EPS $(0.20) Beats $(0.25) Estimate, Sales $5.76M Miss $6.80M Estimate
Benzinga Newsdesk - Nov 9, 2023, 4:27PM
Earnings Scheduled For November 9, 2023
Benzinga Insights - Nov 9, 2023, 6:52AM

Tuesday, October 24, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Benzinga Insights - Oct 24, 2023, 11:00AM
Stifel Initiates Coverage On ClearPoint Neuro with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk - Oct 24, 2023, 4:46AM

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Wednesday, August 09, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Aug 9, 2023, 12:27PM
Lake Street Maintains Buy on ClearPoint Neuro, Lowers Price Target to $15
Benzinga Newsdesk - Aug 9, 2023, 10:23AM

Tuesday, August 08, 2023

ClearPoint Neuro Sees FY23 Revenue $25M-$27M Vs $25.9M Est
Benzinga Newsdesk - Aug 8, 2023, 5:37PM
ClearPoint Neuro Q2 EPS $(0.29) Misses $(0.19) Estimate, Sales $5.95M Beat $5.90M Estimate
Benzinga Newsdesk - Aug 8, 2023, 5:23PM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Thursday, July 06, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Jul 6, 2023, 12:58PM

Friday, June 09, 2023

Top 5 Health Care Stocks That Are Set To Fly In Q2
Lisa Levin - Jun 9, 2023, 8:40AM

Monday, June 05, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Jun 5, 2023, 12:23PM

Wednesday, May 24, 2023

ClearPoint Neuro And UCB Enter License Agreement For Gene Therapy Drug Delivery
Benzinga Newsdesk - May 24, 2023, 9:26AM

Thursday, May 11, 2023

ClearPoint Neuro: Q1 Earnings Insights
Benzinga Insights - May 11, 2023, 4:50PM
ClearPoint Neuro Reaffirms FY23 Revenue Outlook Of $25M-$27M, Consensus $25.91M
Benzinga Newsdesk - May 11, 2023, 4:47PM
ClearPoint Neuro Q1 EPS $(0.23) Vs. $(0.17) Prior Year, Sales $5.43M Beat $5.10M Estimate
Benzinga Newsdesk - May 11, 2023, 4:21PM
Earnings Scheduled For May 11, 2023
Benzinga Insights - May 11, 2023, 9:58AM

Tuesday, April 18, 2023

ClearPoint Neuro Announces Agreement With NE Scientific To Integrate Gene Therapy Infusion Coverage Tool Into ClearPoint Maestro Brain Model
Happy Mohamed - Apr 18, 2023, 4:14PM

Thursday, April 13, 2023

ClearPoint Neuro Announces ANVISA Approval Of Neuro Navigation Portfolio In Brazil
Benzinga Newsdesk - Apr 13, 2023, 4:09PM

Tuesday, April 11, 2023

ClearPoint Neuro Extends Software License, Research Agreement With Philips To Include Fully Automatic Subnuclei Segmentation For DBS
Michael Horton - Apr 11, 2023, 4:07PM

Tuesday, March 28, 2023

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement With UCSF For Innovative Intra-Cerebral Cellular Delivery Platform
Happy Mohamed - Mar 28, 2023, 4:16PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved